Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 2/20 | 1.00 |
| ▸ | ESR1 | P03372 | 5/20 | 0.82 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | GAA | P10253 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.82 |
| ▸ | POLB | P06746 | 1/20 | 0.82 |
| ▸ | G6PD | P11413 | 1/20 | 0.82 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 0.82 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8584056 | 1.00 | SHBG (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL29565170 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL225052 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL13123058 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL225053 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL6010005 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL15491309 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL12027476 | 0.90 | ESR1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL4206797 | 0.87 | CYP19A1 (1.00) | SHBGESR1ESR2LMNAMEN1 | |
| SCHEMBL12820981 | 0.87 | CYP19A1 (1.00) | SHBGESR1ESR2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988209-B | Enylated estradiol compound and preparation and application thereof | 浙江工业大学 | 2020-08-28 | — | — | CN | disclosed |
| CN-101568547-B | Substituted estratriene derivatives as 17 beta HSD inhibitors | SOLVAY PHARM GMBH | 2014-06-25 | — | — | CN | disclosed |
| US-8435973-B2 | 17-beta HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8288367-B2 | Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one | SOLVAY PHARMACEUTICALS GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-8030298-B2 | 17β-HSD1 and STS inhibitors | ABBOTT PRODUCTS GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | SOLVAY PHARMACEUTICALS GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| CN-101568547-A | Substituted estratriene derivatives as 17 beta HSD inhibitors | SOLVAY PHARM GMBH (DE) | 2009-10-28 | — | — | CN | disclosed |
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20070275935-A1 | Estratriene Derivatives | CRYPTOPHARMA PTY LTD (AU) | 2007-11-29 | — | — | US | disclosed |
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | SOLVAY PHARMACEUTICALS GMBH | 2006-12-14 | — | — | US | disclosed |
| CN-1867577-A | Estratriene derivatives | CRYPTOPHARMA PTY LTD (AU) | 2006-11-22 | — | — | CN | disclosed |
| EP-1625143-A1 | ESTRATRIENE DERIVATIVES | Cryptopharma Pty Ltd (AU) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004101595-A1 | ESTRATRIENE DERIVATIVES | CRYPTOPHARMA PTY LTD (AU) | 2004-11-25 | — | — | WO | disclosed |
| EP-0147155-A2 | Improved method of preparing 2-Fluoro-17beta-estradiol | ELI LILLY AND COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4522758-A | Method of preparing 2-fluoro-17β-estradiol | ELI LILLY AND COMPANY (US) | 1985-06-11 | — | — | US | disclosed |
| US-4205952-A | METALLO-HAPTEN, METALLO-BINDER LABELLED COMPONENT | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 1980-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | HSD17B11, HSD17B1, HSD17B2 | SHBG 26/4885ESR1 113/4885ESR2 57/4885 |
| US-20060281710-A1 | 17SS-HSD1 and STS inhibitors | HSD17B11, HSD17B1, STS | SHBG 29/4885ESR1 88/4885ESR2 72/4885 |
| US-20070275935-A1 | Estratriene Derivatives | ESR2, ESRRB, NR3C2 | SHBG 62/4885ESR1 5/4885ESR2 1/4885 |
| US-20110021480-A1 | 17-beta HSD1 and STS Inhibitors | STS, HSD17B11, HSD17B1 | SHBG 24/4885ESR1 206/4885ESR2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.